

SECTION 1: Identification of the substance/mixture and of the company/undertaking

- **1.1 Product identifier**
- **Trade name:** human Adrenergic β 3 Receptor
- **Product number:** ES-035-M400UA
- **1.2 Relevant identified uses of the substance or mixture and uses advised against**
- **Product category** PC21 Laboratory chemicals
- **Application of the substance / the mixture** Laboratory chemicals
- **1.3 Details of the supplier of the safety data sheet**
- **Manufacturer/Supplier:**
Revvity, Inc
549 Albany Street
Boston, MA 02118
- **Further information obtainable from:**
US Technical Support
800-762-4000
- **1.4 Emergency telephone number:**
If inside USA, call CHEMTREC at 1-800-424-9300
If outside USA, call CHEMTREC at 1-703-527-3887

SECTION 2: Hazards identification

- **2.1 Classification of the substance or mixture**
- **2.1.1 Classification according to Regulation (EC) No 1272/2008**
The product is not classified, according to the CLP regulation.
- **2.2 Label elements**
- **Labelling according to Regulation (EC) No 1272/2008** Void
- **Hazard pictograms** Void
- **Signal word** Void
- **Hazard statements** Void
- **2.3 Other hazards**
- **Results of PBT and vPvB assessment**
- **PBT:** Not applicable.
- **vPvB:** Not applicable.

SECTION 3: Composition/information on ingredients

- **3.2 Mixtures**
- **Description:** Mixture of substances listed below with nonhazardous additions.
- **Dangerous components:** Void
- **Additional information:** For the wording of the relevant risk phrases refer to section 16.

SECTION 4: First aid measures

- **4.1 Description of first aid measures**
- **General information:** No special measures required.
- **After inhalation:** Supply fresh air; consult doctor in case of complaints.
- **After skin contact:** If skin irritation continues, consult a doctor.
- **After eye contact:** Rinse opened eye for several minutes under running water.
- **After swallowing:** If symptoms persist consult doctor.
- **4.2 Most important symptoms and effects, both acute and delayed** No further relevant information available.

(Contd. on page 2)

Safety data sheet
according to 1907/2006/EC, Article 31

Printing date 20.02.2024

Version number 1

Revision: 16.08.2023

Trade name: human Adrenergic β 3 Receptor

(Contd. of page 1)

- **4.3 Indication of any immediate medical attention and special treatment needed**
No further relevant information available.

SECTION 5: Firefighting measures

- **5.1 Extinguishing media**
- **Suitable extinguishing agents:** Use fire extinguishing methods suitable to surrounding conditions.
- **5.2 Special hazards arising from the substance or mixture** No further relevant information available.
- **5.3 Advice for firefighters**
- **Protective equipment:** Wear self-contained respiratory protective device.

SECTION 6: Accidental release measures

- **6.1 Personal precautions, protective equipment and emergency procedures** Not required.
- **6.2 Environmental precautions:** Do not allow to enter sewers/ surface or ground water.
- **6.3 Methods and material for containment and cleaning up:**
Absorb with liquid-binding material (sand, diatomite, acid binders, universal binders, sawdust).
- **6.4 Reference to other sections**
See Section 7 for information on safe handling.
See Section 8 for information on personal protection equipment.
See Section 13 for disposal information.

SECTION 7: Handling and storage

- **7.1 Precautions for safe handling** No special measures required.
- **Information about fire - and explosion protection:** No special measures required.
- **7.2 Conditions for safe storage, including any incompatibilities**
- **Storage:**
- **Requirements to be met by storerooms and containers:** No special requirements.
- **Information about storage in one common storage facility:** Not required.
- **Further information about storage conditions:** None.
- **Storage class:** 12
- **7.3 Specific end use(s)** No further relevant information available.

SECTION 8: Exposure controls/personal protection

- **8.1 Control parameters**
- **Ingredients with limit values that require monitoring at the workplace:**
The product does not contain any relevant quantities of materials with critical values that have to be monitored at the workplace.
- **8.2 Exposure controls**
- **Appropriate engineering controls** No further data; see section 7.
- **Individual protection measures, such as personal protective equipment**
- **General protective and hygienic measures:**
The usual precautionary measures are to be adhered to when handling chemicals.
- **Respiratory protection:** Not required.
- **Hand protection**
The glove material has to be impermeable and resistant to the product/ the substance/ the preparation.
Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation

(Contd. on page 3)

Safety data sheet

according to 1907/2006/EC, Article 31

Printing date 20.02.2024

Version number 1

Revision: 16.08.2023

Trade name: human Adrenergic β 3 Receptor

(Contd. of page 2)

· **Material of gloves**

The selection of the suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer. As the product is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

· **Penetration time of glove material**

The exact break through time has to be found out by the manufacturer of the protective gloves and has to be observed.

· **Eye/face protection** Goggles recommended during refilling

SECTION 9: Physical and chemical properties

· **9.1 Information on basic physical and chemical properties**

· **General Information**

· Physical state	Fluid
· Colour:	According to product specification
· Odour:	Characteristic
· Odour threshold:	Not determined.
· Melting point/freezing point:	Undetermined.
· Boiling point or initial boiling point and boiling range	100 °C
· Flammability	Not applicable.
· Lower and upper explosion limit	
· Lower:	Not determined.
· Upper:	Not determined.
· Flash point:	Not applicable.
· Decomposition temperature:	Not determined.
· pH	Not determined.
· Viscosity:	
· Kinematic viscosity	Not determined.
· Dynamic:	Not determined.
· Solubility	
· water:	Not miscible or difficult to mix.
· Partition coefficient n-octanol/water (log value)	Not determined.
· Vapour pressure at 20 °C:	23 hPa
· Density and/or relative density	
· Density:	Not determined.
· Relative density	Not determined.
· Vapour density	Not determined.

· **9.2 Other information**

· Appearance:	
· Form:	Fluid
· Important information on protection of health and environment, and on safety.	
· Ignition temperature:	Product is not selfigniting.
· Explosive properties:	Product does not present an explosion hazard.
· Solvent content:	
· Water:	86.4 %
· Solids content:	12.6 %
· Change in condition	
· Evaporation rate	Not determined.

· **Information with regard to physical hazard classes**

· Explosives	Void
---------------------	------

(Contd. on page 4)

Safety data sheet
according to 1907/2006/EC, Article 31

Printing date 20.02.2024

Version number 1

Revision: 16.08.2023

Trade name: human Adrenergic β 3 Receptor

(Contd. of page 3)

· Flammable gases	Void
· Aerosols	Void
· Oxidising gases	Void
· Gases under pressure	Void
· Flammable liquids	Void
· Flammable solids	Void
· Self-reactive substances and mixtures	Void
· Pyrophoric liquids	Void
· Pyrophoric solids	Void
· Self-heating substances and mixtures	Void
· Substances and mixtures, which emit flammable gases in contact with water	Void
· Oxidising liquids	Void
· Oxidising solids	Void
· Organic peroxides	Void
· Corrosive to metals	Void
· Desensitised explosives	Void

SECTION 10: Stability and reactivity

- **10.1 Reactivity** No further relevant information available.
- **10.2 Chemical stability**
- **Thermal decomposition / conditions to be avoided:** No decomposition if used according to specifications.
- **10.3 Possibility of hazardous reactions** No dangerous reactions known.
- **10.4 Conditions to avoid** No further relevant information available.
- **10.5 Incompatible materials:** No further relevant information available.
- **10.6 Hazardous decomposition products:** No dangerous decomposition products known.

SECTION 11: Toxicological information

- **11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008**
- **Acute toxicity** Based on available data, the classification criteria are not met.
- **Skin corrosion/irritation** Based on available data, the classification criteria are not met.
- **Serious eye damage/irritation** Based on available data, the classification criteria are not met.
- **Respiratory or skin sensitisation** Based on available data, the classification criteria are not met.
- **Germ cell mutagenicity** Based on available data, the classification criteria are not met.
- **Carcinogenicity** Based on available data, the classification criteria are not met.
- **Reproductive toxicity** Based on available data, the classification criteria are not met.
- **STOT-single exposure** Based on available data, the classification criteria are not met.
- **STOT-repeated exposure** Based on available data, the classification criteria are not met.
- **Aspiration hazard** Based on available data, the classification criteria are not met.
- **11.2 Information on other hazards**

- **Endocrine disrupting properties**

None of the ingredients is listed.

SECTION 12: Ecological information

- **12.1 Toxicity**
- **Aquatic toxicity:** No further relevant information available.
- **12.2 Persistence and degradability** No further relevant information available.

(Contd. on page 5)

Safety data sheet
according to 1907/2006/EC, Article 31

Printing date 20.02.2024

Version number 1

Revision: 16.08.2023

Trade name: human Adrenergic β 3 Receptor

(Contd. of page 4)

- **12.3 Bioaccumulative potential** No further relevant information available.
- **12.4 Mobility in soil** No further relevant information available.
- **12.5 Results of PBT and vPvB assessment**
- **PBT:** Not applicable.
- **vPvB:** Not applicable.
- **12.6 Endocrine disrupting properties**
The product does not contain substances with endocrine disrupting properties.
- **12.7 Other adverse effects** No further relevant information available.

SECTION 13: Disposal considerations

- **13.1 Waste treatment methods**
- **Recommendation**
Smaller quantities can be disposed of with household waste.
Must be specially treated adhering to official regulations.
- **Uncleaned packaging:**
- **Recommendation:** Disposal must be made according to official regulations.

SECTION 14: Transport information

· 14.1 UN number or ID number · ADR, ADN, IMDG, IATA	Void
· 14.2 UN proper shipping name · ADR, ADN, IMDG, IATA	Void
· 14.3 Transport hazard class(es) · ADR, ADN, IMDG, IATA · Class	Void
· 14.4 Packing group · ADR, IMDG, IATA	Void
· 14.5 Environmental hazards:	Not applicable.
· 14.6 Special precautions for user	Not applicable.
· 14.7 Maritime transport in bulk according to IMO instruments	Not applicable.
· UN "Model Regulation":	Void

SECTION 15: Regulatory information

- **15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**
- **Directive 2012/18/EU**
- **Named dangerous substances - ANNEX I** None of the ingredients is listed.
- **DIRECTIVE 2011/65/EU on the restriction of the use of certain hazardous substances in electrical and electronic equipment – Annex II**
None of the ingredients is listed.

(Contd. on page 6)

Safety data sheet
according to 1907/2006/EC, Article 31

Printing date 20.02.2024

Version number 1

Revision: 16.08.2023

Trade name: human Adrenergic β 3 Receptor

(Contd. of page 5)

· **REGULATION (EU) 2019/1148**

· **Annex I - RESTRICTED EXPLOSIVES PRECURSORS (Upper limit value for the purpose of licensing under Article 5(3))**

None of the ingredients is listed.

· **Annex II - REPORTABLE EXPLOSIVES PRECURSORS**

None of the ingredients is listed.

· **Regulation (EC) No 273/2004 on drug precursors**

None of the ingredients is listed.

· **Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Community and third countries in drug precursors**

None of the ingredients is listed.

· **15.2 Chemical safety assessment:** A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

The information provided in this safety data sheet is based on our current knowledge, and is believed to be correct at the date of publication. However, no representation is made concerning its accuracy and completeness. It is intended as guidance only, and is not to be regarded as a warranty or specification of quality. All materials may present unknown hazards and should be used with caution. Although certain hazards are described, we cannot guarantee that these are the only hazards that exist. Revvity, Inc. cannot be held liable for any damage resulting from handling or contact with the product.

· **Abbreviations and acronyms:**

ADR: Accord relatif au transport international des marchandises dangereuses par route (European Agreement Concerning the International Carriage of Dangerous Goods by Road)

IMDG: International Maritime Code for Dangerous Goods

IATA: International Air Transport Association

GHS: Globally Harmonised System of Classification and Labelling of Chemicals

EINECS: European Inventory of Existing Commercial Chemical Substances

ELINCS: European List of Notified Chemical Substances

CAS: Chemical Abstracts Service (division of the American Chemical Society)

PBT: Persistent, Bioaccumulative and Toxic

vPvB: very Persistent and very Bioaccumulative

EU